Hyperglycemia and Oxidative Stress Strengthen the Association Between Myeloperoxidase and Blood Pressure
Authors:
- 1 June 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 55 (6) , 1366-1372
Abstract
Scavenging of the vasodilator nitric oxide by myeloperoxidase activity in the vasculature may contribute to hypertension. Because hydrogen peroxide is a cosubstrate of myeloperoxidase, hyperglycemia-induced oxidative stress may strengthen the relationship between myeloperoxidase and blood pressure. We investigated this relationship and its modification by hyperglycemia and oxidative stress in a population-based cohort of elderly subjects with normal glucose metabolism (n=267), impaired glucose metabolism (n=189), and type 2 diabetes (n=290). In an age- and sex-adjusted linear regression model, plasma myeloperoxidase was positively associated with systolic blood pressure (2.10 mm Hg per 1 SD increment of myeloperoxidase [95% CI: 0.66 to 3.54]), and this association was stronger at higher levels of fasting glucose (0.61 [−1.70 to 2.93], 1.33 [−1.43 to 4.10], and 3.42 [1.01 to 5.82] for increasing tertiles of glucose) and higher plasma levels of oxidized low-density lipoprotein (0.92 [−1.31 to 3.14], 2.00 [−0.71 to 4.70], and 3.58 [0.98 to 6.19] for increasing tertiles of oxidized low-density lipoprotein). Likewise, the relationship between myeloperoxidase and blood pressure was strongest under conditions associated with oxidative stress, like obesity, low high-density lipoprotein cholesterol, metabolic syndrome, and type 2 diabetes. The strength of these associations was only marginally attenuated by adjustment for other cardiovascular risk factors. Our data demonstrate that myeloperoxidase is positively and independently associated with blood pressure, and this association is strongest in subjects with (hyperglycemia-induced) oxidative stress. These observations, together with emerging evidence that myeloperoxidase-derived oxidants contribute to the initiation and propagation of cardiovascular disease, identify myeloperoxidase as a promising target for drug development.Keywords
This publication has 33 references indexed in Scilit:
- Association of serum myeloperoxidase with the ankle–brachial index and peripheral arterial diseaseVascular Medicine, 2009
- Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?Clinical Chemistry, 2009
- Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy IndividualsJACC, 2007
- Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial InfarctionJACC, 2007
- Myeloperoxidase and Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Myeloperoxidase: friend and foeJournal of Leukocyte Biology, 2005
- Is hypertension an inflammatory disease?Medical Hypotheses, 2005
- Leukocyte-Derived Myeloperoxidase Amplifies High-Glucose—Induced Endothelial Dysfunction Through Interaction With High-Glucose—Stimulated, Vascular Non—Leukocyte-Derived Reactive Oxygen SpeciesDiabetes, 2004
- Prognostic Value of Myeloperoxidase in Patients with Chest PainNew England Journal of Medicine, 2003
- Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary SyndromesCirculation, 2003